ArticleWorld journal of transplantation2026
Adrenal metastasis of hepatocellular carcinoma after liver transplantation: Case report and systematic review of literature.
Article in World journal of transplantation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAdrenal metastasis of hepatocellular carcinoma (AM-HCC) after liver transplantation (LT) is an infrequent entity, especially when it is the only site of recurrence. We present patients with these characteristics and systematically review previously published cases. No systematic review adhering to PRISMA criteria has been previously performed.
aimTo systematic review of isolated AM-HCC after LT.
methodsAdhering to PRISMA guidelines, we performed unrestricted search for AM-HCC after LT in several databases, with no language restriction, updated through December 31, 2024.
resultsWe obtained 38 articles. Only 14 articles, comprising 20 patients, were evaluated, to which we added our own case. Fourteen were single-case reports, and one was a series of seven retrospective cases. The median age was 56.1 years [interquartile range (IQR): 23-72]. The gender distribution was predominantly male (84.6%). The indications for LT were hepatocellular carcinoma (HCC) plus hepatitis B virus cirrhosis (11), hepatitis C virus (6), alcohol (3), and cryptogenic cirrhosis (1). The median HCC tumor size was 4.6 cm (IQR: 3.8-13). One third of patients did not meet the Milan criteria. The median time between LT and the appearance of adrenal metastasis (AM) was 39.9 months (IQR: 18-42.6)
conclusionIn the case of AM-HCC after LT, occurring as the solitary site of extrahepatic metastasis, adrenalectomy could be a therapeutic option for surgical candidates. It is safe, appears to increase survival, and reduces recurrence in selected patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.